Table 2.
Treatment exposure history
| Ustekinumab cohort (n=20) | Anti-TNF cohort (n=40) | |
|---|---|---|
| Immunomodulators | ||
| Azathioprine | 11 (55%) | 11 (27.5%) |
| Methotrexate | 6 (30%) | 9 (22.5%) |
| Previous anti-TNF therapy | ||
| Infliximab | 20 (100%) | 7 (17.5) |
| Adalimumab | 13 (65%) | 4 (10%) |
| Certolizumab | 1 (5%) | 0 |
| Golimumab | 3 (15%) | 0 |
| Previously biologic naive | 0 | 31 (77.5%) |
| Failed 1 anti-TNF therapies | 6 (30%) | 7 (17.5%) |
| Failed 2 anti-TNF therapies | 11 (55%) | 2 (5%) |
| Failed 3 anti-TNF therapies | 3 (15%) | 0 |
| Other previous biologics exposure (commercial/clinical trials) | ||
| Vedolizumab | 1 (5%) | 0 |
| Ustekinumab | - | 1 (2.5%) |
| Briakinumab (ABT-894) | 0 | 1 (2.5%) |
| CCR-9 inhibitor | 1 (5%) | 0 |